Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
N650869-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$385.90
|
|
|
N650869-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$660.90
|
|
|
N650869-50mg
|
50mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$2,200.90
|
|
| Synonyms | 2244614-14-8 | 1-(6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)piperidin-4-amine | F82370 | 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5- yl)quinolin-2-yl]-N-(oxan-4-yl)piperidin-4-ami |
|---|---|
| Specifications & Purity | ≥99% |
| Biochemical and Physiological Mechanisms | Navacaprant (BTRX-335140) is a selective and orally active κ opioid receptor (KOR) antagonist, has antagonist activity for κOR, μOR and δOR with IC 50 values of 0.8 nM, 110 nM, and 6500 nM, respectively.\nNavacaprant endows with favorable in vitro ADMET a |
| Storage Temp | Store at -20°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Product Description |
Navacaprant (BTRX-335140) is a selective and orally active κ opioid receptor (KOR) antagonist, has antagonist activity for κOR, μOR and δOR with IC 50 values of 0.8 nM, 110 nM, and 6500 nM, respectively.Navacaprant endows with favorable in vitro ADMET and in vivo pharmacokinetic profiles and medication-like duration of action in rats. Navacaprant distributes well into the CNS and can be used for the research of neuropathy In Vitro Navacaprant (BTRX-335140) (0-10 μM; 4 h) shows selective antagonist activity towards Kappa Opioid Receptor. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: OPRK1-BLA U2OS cells Concentration: 0-10 μM Incubation Time: 4 hours Result: Exibited antagonist activity to KOR, DOR and MOR with IC 50 values of 0.8, 110 and 6500 nM respectively, and showed selective antagonist activity to KOR. In Vivo Navacaprant (BTRX-335140) (0.01-3 mg/kg; p.o. once) reduces U69,593- stimulated plasma prolactin secretion to levels of without U69,593 treatment . Navacaprant (BTRX-335140) (1 mg/kg; i.p. once) blocks U-50488-induced antinociception from hot water . 1.19 Pharmacokinetic Parameters of BTRX-335140 in rodents . Rats IV 1 mg/kg Mice IV 3 mg/kg Rats PO 5 mg/kg Mice PO 10 mg/kg CL (mL/min/kg) 105 66.5 t 1/2 (h) 1.81 1.91 6.19 2.57 AUC 0-t (h•ng/mL) 153 725 265 232 V ss (L/kg) 13.8 7.72 F (%) 30.2 12 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Rat PRL model Dosage: 0.01, 0.03, 0.1, 0.3, 1 and 3 mg/kg Administration: Oral gavage; 0.01-3 mg/kg once Result: Effectively decreased the high level prolactin caused by U69,593 even at a dosage of 0.1 mg/kg. Animal Model: Adult male ICR mice with tail dipped into 50°C hot water Dosage: 1 mg/kg Administration: Intraperitoneal injection; 1 mg/kg once Result: Blocked the U-50488-induced antinociception at 1 h but not at 24 h pretreatment time and showed a medication-like duration of action in blocking the KOR. Form:Solid IC50& Target:κ Opioid Receptor/KOR 0.8 nM (IC 50 ) μ Opioid Receptor/MOR 110 nM (IC 50 ) δ Opioid Receptor/DOR 6500 nM (IC 50 ) |
Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organoheterocyclic compounds |
| Class | Quinolines and derivatives |
| Subclass | Aminoquinolines and derivatives |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Aminoquinolines and derivatives |
| Alternative Parents | Haloquinolines Dialkylarylamines Methylpyridines Aminopyridines and derivatives Aminopiperidines Oxanes Imidolactams Benzenoids Aryl fluorides Heteroaromatic compounds 1,2,4-oxadiazoles Oxacyclic compounds Dialkylamines Dialkyl ethers Azacyclic compounds Organopnictogen compounds Organofluorides Hydrocarbon derivatives |
| Molecular Framework | Aromatic heteropolycyclic compounds |
| Substituents | Haloquinoline - Aminoquinoline - Dialkylarylamine - Methylpyridine - Aminopyridine - 4-aminopiperidine - Imidolactam - Benzenoid - Pyridine - Piperidine - Oxane - Aryl halide - Aryl fluoride - Heteroaromatic compound - Oxadiazole - Azole - 1,2,4-oxadiazole - Oxacycle - Azacycle - Secondary amine - Ether - Secondary aliphatic amine - Dialkyl ether - Organic nitrogen compound - Organic oxygen compound - Organopnictogen compound - Hydrocarbon derivative - Organooxygen compound - Organonitrogen compound - Organofluoride - Organohalogen compound - Amine - Aromatic heteropolycyclic compound |
| Description | This compound belongs to the class of organic compounds known as aminoquinolines and derivatives. These are organic compounds containing an amino group attached to a quinoline ring system. |
| External Descriptors | Not available |
|
|
|
| ALogP | 4.7 |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| IUPAC Name | 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-N-(oxan-4-yl)piperidin-4-amine |
|---|---|
| INCHI | InChI=1S/C25H32FN5O2/c1-4-17-13-20-15(2)22(25-27-16(3)30-33-25)24(29-23(20)21(26)14-17)31-9-5-18(6-10-31)28-19-7-11-32-12-8-19/h13-14,18-19,28H,4-12H2,1-3H3 |
| InChIKey | CQOJHAJWCDJEAT-UHFFFAOYSA-N |
| Smiles | CCC1=CC2=C(C(=C(N=C2C(=C1)F)N3CCC(CC3)NC4CCOCC4)C5=NC(=NO5)C)C |
| Isomeric SMILES | CCC1=CC2=C(C(=C(N=C2C(=C1)F)N3CCC(CC3)NC4CCOCC4)C5=NC(=NO5)C)C |
| Alternate CAS | 2244614-14-8 |
| PubChem CID | 137434175 |
| MeSH Entry Terms | 1-(6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)- N-(tetrahydro-2 H-pyran-4-yl)piperidin-4 amine;BTRX-335140;CYM-53093 |
| Molecular Weight | 453.55 |
| Solubility | DMSO : 16.67 mg/mL (36.75 mM; Need ultrasonic) |
|---|---|
| Molecular Weight | 453.600 g/mol |
| XLogP3 | 4.700 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 5 |
| Exact Mass | 453.254 Da |
| Monoisotopic Mass | 453.254 Da |
| Topological Polar Surface Area | 76.300 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 630.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |